Dossier assessment
Nintedanib (systemic sclerosis associated interstitial lung disease in adults) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Nintedanib (systemic sclerosis associated interstitial lung disease in adults) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Nintedanib (systemic sclerosis associated interstitial lung disease in adults) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
| Adults with systemic sclerosis associated interstitial lung disease (SSc-ILD) |
| Exclusively negative effects, particularly regarding side effects; indication of lesser benefit in comparison with the appropriate comparator therapy |
Project details
- Project no.
- A20-70
- Commission
- Commission awarded on 12.08.2020 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Airways and respiratory system
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Nintedanib (idiopathic pulmonary fibrosis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nintedanib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)
Status: Commission completed
-
Dossier assessment
Nintedanib - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Status: Commission completed
-
Dossier assessment
Nintedanib (interstitial lung disease) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nintedanib (fibrosing interstitial lung diseases, 6 to < 18 years) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nintedanib (systemic sclerosis associated interstitial lung disease, 6 to < 18 years) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed